Emerging Breast Cancer Therapies and Closing Thoughts

Anna Mueller, MD, and Amir Ahmadi, MD, of Mount Sinai, highlight gaps in risk assessment tools for acute coronary syndrome, calling for more comprehensive screening strategies.

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

Researchers found low rates of patient involvement in first-line ovarian cancer treatment decisions in Europe and the US from 2017 to 2020 despite the increasing use of targeted therapies, like poly (ADP-ribose) polymerase inhibitors.

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

Jason Romancik, MD, a board-certified hematologist at Emory Winship Cancer Institute, discusses the current treatment landscape in aggressive lymphoma and drivers of high care costs.

New STEP-HFpEF findings presented at this year’s European Society of Cardiology Congress add to the many accolades this glucagon-like peptide-1 receptor agonist has already received for the numerous benefits it can produce among patients living with heart failure with preserved ejection fraction.